Grandisin

Pharmacology & Research

Grandisin is a symmetrical tetrahydrofuran (diaryl-furanoid) lignan — a relative of sesamin and episesamin — from Virola surinamensis, Piper solmsianum and other tropical plants. One provenance point is load-bearing: grandisin is non-psychoactive and must not inherit the epeña (Virola theiodora) snuff’s psychoactivity or legal status — its pharmacology comes from V. surinamensis/Piper, not the snuff. Its genuine hook is antiparasitic (trypanocidal/antileishmanial), with larvicidal, antinociceptive and antiangiogenic signals alongside; all evidence is preclinical, and several of the strongest antiparasitic results are actually synthetic analogues of grandisin.

1. Antiparasitic

Grandisin’s genuine hook. It is one of the trypanocidal tetrahydrofuran lignans of Piper solmsianum ^{2Reference 22003Trypanocidal tetrahydrofuran lignans from the inflorescences of Piper solmsianumView study →} and part of the Virola surinamensis twig fraction active against Trypanosoma cruzi in vitro ^{3Reference 31998Flavonoids and lignans from Virola surinamensis twigs and their in-vitro activity against Trypanosoma cruziView study →}; the Virola neolignan series is antileishmanial ^{4Reference 42000Antileishmanial activity of neolignans from Virola species and synthetic analoguesView study →}, and grandisin-derived triazolic and isoxazole analogues extend the antileishmanial/antitrypanosomatid activity ^{7,8Reference 72016Antileishmanial activity and SAR of triazolic compounds derived from the neolignans grandisin, veraguensin and machilin GView study →Reference 82019Design, synthesis and antitrypanosomatid activities of 3,5-diaryl-isoxazole analogues based on veraguensin, grandisin and machilin GView study →}, with synthetic diaryl-THF analogues implicating trypanothione reductase inhibition ^{9Reference 92017Synthesis and 2D-QSAR of neolignan-based diaryl-tetrahydrofuran analogues active against T. cruzi; trypanothione-reductase assessmentView study →}.

Gap: all in-vitro, with no animal efficacy or human data for isolated grandisin — and several of the strongest results are analogues, not grandisin itself ^{2,9Reference 22003Trypanocidal tetrahydrofuran lignans from the inflorescences of Piper solmsianumView study →Reference 92017Synthesis and 2D-QSAR of neolignan-based diaryl-tetrahydrofuran analogues active against T. cruzi; trypanothione-reductase assessmentView study →}.

2. Insecticidal

Grandisin is larvicidal against Aedes aegypti larvae ^{5Reference 52009Larvicidal activity of grandisin against Aedes aegyptiView study →} and disrupts the development/growth of the blowfly Chrysomya megacephala ^{6Reference 62009Disruption of Chrysomya megacephala growth caused by the lignan grandisinView study →}.

Gap: purely entomological (vector/forensic-fly models), with no relevance to human systemic use and no mechanism established ^{5,6Reference 52009Larvicidal activity of grandisin against Aedes aegyptiView study →Reference 62009Disruption of Chrysomya megacephala growth caused by the lignan grandisinView study →}.

3. Anti-inflammatory / antinociceptive

In mice, grandisin dose-dependently reduced acetic-acid writhing, cut inflammatory-phase (formalin) pain and reduced ear oedema, without sedation ^{10Reference 102010Antinociceptive and anti-inflammatory activities of grandisin extracted from Virola surinamensisView study →}.

Gap: a single study from one lab, with no mechanism defined and no dose-translation or human data ^{10Reference 102010Antinociceptive and anti-inflammatory activities of grandisin extracted from Virola surinamensisView study →}.

4. Anticancer

Grandisin showed cytotoxicity and antiangiogenic activity in vitro, and has been described as a candidate anticancer lignan ^{1Reference 12009Cytotoxicity and antiangiogenic activity of grandisinView study →}.

Gap: cytotoxicity is modest and in-vitro only — “anticancer candidate” is an aspiration, not demonstrated efficacy ^{1Reference 12009Cytotoxicity and antiangiogenic activity of grandisinView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Trypanosoma cruzi / Leishmania (in vitro)	direct growth inhibition	antiparasitic
Trypanothione reductase (diaryl-THF analogues)	inhibition (proposed mechanism)	antiparasitic
Insect larval/pupal development	larvicidal / growth disruption	insecticidal
Inflammatory & nociceptive response	reduced, no sedation (mechanism undefined)	anti-inflammatory / analgesic
Endothelial angiogenesis + tumour-cell viability	antiangiogenic + cytotoxic in vitro	anticancer (preclinical)
Human CYP1A2, 2C9, 3A4/5, 2D6, 2E1	in-vitro inhibition	herb–drug-interaction flag

Pharmacokinetics

Grandisin is a lipophilic diaryl-tetrahydrofuran lignan with poor aqueous solubility and, by class, low expected oral bioavailability (no measured F). No in-vivo pharmacokinetics have been published; what exists is in-vitro metabolism only — human liver microsomes extensively metabolise (−)-grandisin via phase-I oxidative routes (O-demethylation/hydroxylation of the trimethoxyphenyl rings), consistent with rapid hepatic first-pass turnover ^{11Reference 112013In-vitro metabolism study of the promising anticancer agent, the lignan (−)-grandisinView study →}. Because grandisin both inhibits major CYPs ^{12Reference 122017In-vitro inhibition of human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by grandisinView study →} and is a CYP substrate, it carries a herb–drug-interaction flag, and its pharmacokinetics are inferred/in-vitro rather than characterised in humans or animals.

Clinical trials

There are no clinical trials of isolated grandisin — no registered or published human studies — and all evidence is in-vitro or rodent/insect preclinical.

Last checked: July 2026.

Toxicity & Safety

Grandisin has a low intrinsic-toxicity signal that is formally uncharacterised — the rodent antinociception study reported activity without sedation ^{10Reference 102010Antinociceptive and anti-inflammatory activities of grandisin extracted from Virola surinamensisView study →}, but no acute-toxicity, genotoxicity or repeat-dose studies of the isolate exist, so [low] reflects analogy to other dietary lignans and the absence of adverse signals rather than proven safety. Two theoretical cautions belong on the page: grandisin is deliberately larvicidal/insecticidal ^{5,6Reference 52009Larvicidal activity of grandisin against Aedes aegyptiView study →Reference 62009Disruption of Chrysomya megacephala growth caused by the lignan grandisinView study →} and antiangiogenic/cytotoxic in vitro ^{1Reference 12009Cytotoxicity and antiangiogenic activity of grandisinView study →}, and it is a pan-CYP inhibitor in vitro, so it carries a herb–drug-interaction flag with co-administered CYP substrates ^{12Reference 122017In-vitro inhibition of human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by grandisinView study →}.

Pregnancy & lactation

Avoid / insufficient data. No reproductive or developmental data exist, and the demonstrated antiangiogenic/cytotoxic and insecticidal activities make caution appropriate — grandisin should not be used as an isolated supplement in pregnancy or lactation.

Dosage

There is no established human or therapeutic dose — all figures in the literature are in-vitro concentrations or rodent/insect experimental doses, and there is no basis for a human dose.

References